Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Cost-effective and Sensitive DNA Methylation Profiling for Advancing Single-Cell Epigenomics

Project description

Advancing epigenetic profiling

Epigenetics refers to changes in gene expression that are heritable but do not involve changes in the DNA sequence. Many studies have shown that epigenetics is implicated in health and diseases such as cancer, neurodegeneration, and autoimmune disorders. The ERC-funded MeTLAND project focuses on DNA methylation, a key epigenetic modification implicated in patient responses to treatment. The goal of the project is to address limitations in existing profiling methods by developing a novel enzyme-based technique for the efficient detection of methylated DNA regions. This method is compatible with most types of analyses and comes at a lower cost, maintains sample integrity, and offers a versatile tool for research and precision medicine.

Objective

Epigenetic dysregulation is a key contributor to numerous major diseases, including cancer, neurodegenerative disorders, and autoimmune conditions, underscoring the critical need for scalable and cost-effective profiling technologies. A central challenge in precision medicine is the heterogeneity in patient responses to treatment, which is influenced by inter-individual epigenetic variability. DNA methylation, a fundamental epigenetic modification, plays a central role in disease pathogenesis and therapeutic outcomes. However, existing methylation profiling methods, such as whole-genome bisulfite sequencing (WGBS) and affinity-based enrichment approaches, are hindered by high costs, technical complexity, and DNA degradation associated with harsh chemical treatments.
To overcome these limitations, we developed MeTLAND, an innovative enzyme-based DNA methylation profiling method that enables efficient and selective detection of methylated regions in a single-step reaction. This streamlined, single-step workflow significantly reduces sample processing time, degradation, and cost. Designed to be broadly compatible with established genomics platforms, MeTLAND also supports integration with other epigenomic assays, facilitating multimodal data generation. Its compatibility with bulk, single-cell, and spatial epigenomic applications further enhances its versatility. With the global epigenomics market valued at $17 billion, MeTLAND addresses the growing need for accessible, high-sensitivity methylation profiling, positioning it as a transformative tool for both research and clinical applications.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

KAROLINSKA INSTITUTET
Net EU contribution
€ 45 000,00
Address
NOBELS VAG 5
171 77 STOCKHOLM
Sweden
Region
Östra Sverige Stockholm Stockholms län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (2)